SterisCare has crossed a significant milestone in its internationalisation journey with the dispatch of its first export consignment to Southeast Asia. The shipment was received by our Malaysian distribution partner, BioPharmEx Sdn Bhd, on 12 February 2026.
The consignment included our core cardiology and diabetology ranges — a combined shipment of 48 SKUs destined for institutional and retail channels across Kuala Lumpur, Penang, and Johor Bahru.
Strategic Significance
This marks SterisCare's entry into the ASEAN pharmaceutical market, valued at over USD 30 billion. The regulatory dossiers for our key products have been submitted to Malaysia's National Pharmaceutical Regulatory Agency (NPRA), with approvals expected progressively through FY2027.
The company is in parallel discussions with distribution partners in Thailand, Vietnam, and the Philippines.
